Brief: Mayne Pharma Says Net Revenues Were A$165 Million For First 5 Months Of FY26
22/12/2025 24:58
Dec 22 (Reuters) - Mayne Pharma Group Ltd MYX.AX: UNDERLYING EBITDA FOR FIRST 5 MONTHS OF FY26 WAS A$11.5M NET REVENUES WERE A$165 MILLION FOR FIRST 5 MONTHS OF FY26 Further company coverage: MYX.AX ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mayne Pharma
See all newsBrief: Mayne Pharma Group Says It Settles Us Patent Litigation Re Imvexxy With Teva USA
Deals of the day-Mergers and acquisitions
Brief: Mayne Pharma Says Supreme Court Dismisses Cosette Appeal
Deals of the day-Mergers and acquisitions
Australian court dismisses Cosette appeal to drop Mayne Pharma takeover (updated)